More than an adventure, WomenCan's Larapinta trek symbolises the unity, and determination towards a critical cause - supporting ANZGOG's research. Three dedicated ANZGOG members: Professor Linda Mileshkin (Medical Oncologist, VIC), Associate Professor Jeffrey Goh (Medical [...]
An additional chemotherapy option for people with advanced leiomyosarcoma is now available on the Pharmaceutical Benefits Scheme (PBS). Trabectedin, (brand name - Yondelis) offers renewed hope for patients facing this rare and challenging sarcoma cancer. [...]
For the first time in Australia, researchers can find clinical trial data from multiple research institutions and request access to it via a new platform, Health Data Australia. ANZGOG is proud to be part of this [...]
Led by ANZGOG co-founder Professor Michael Friedlander AM, PARAGON was one of ANZGOG's first practice-changing studies. The publications arising from the insights and data collected because of this pivotal trial continue to contribute to research on [...]
PORTEC-3 was a randomised phase III study that had a significant impact on the world of gynaecological cancer research. The study was led by LUMC GCIG/Dutch Gynaecological Oncology Group (DGOG), with ANZGOG leading in Australia [...]
With the incidence rate of endometrial cancer nearly doubling in Australia over the past two decades, it is crucial to raise awareness and knowledge about this rapidly rising disease. In response to this, WomenCan is [...]
Uterine cancer and specifically endometrial cancer is the most common gynaecological cancer in Australia, and it is becoming increasingly prevalent both domestically and internationally. In the past ten years, Australia alone has experienced an almost [...]
A Phase II Trial of Tislelizumab in combination with Sitravatinib for Recurrent/Metastatic Cervical Cancer after Platinum-Based Chemotherapy. The ITTACc study is an ANZGOG-developed trial led in Australia by A/Prof Jeffrey Goh from the Royal [...]
The results of the OUTBACK trial, a landmark multinational phase 3 trial investigating the efficacy of adjuvant chemotherapy in women with locally advanced cervical cancer, have been published in The Lancet Oncology. The trial aimed [...]
ANZGOG’s TAPER Study has received $1.27 million in funding from the Australian Government’s Medical Research Future Fund (MRFF) which aims to improve the health and wellbeing of Australians by supporting medical research and innovation. [...]
Australia New Zealand Gynaecological Oncology Group www.anzgog.org.au
Level 6, Lifehouse, 119-143 Missenden Road Camperdown NSW 2050 T:+61 2 8071 4880
E: contact@anzgog.org.au © 2024 ANZGOG | Copyright | Disclaimer | ANZGOG Policies | Whistleblower
Virtually every advance in cancer survival has been made on the back of clinical trials.
As the peak, national gynaecological cancer clinical trials organisation for Australia and New Zealand, ANZGOG‘s purpose is to improve outcomes and quality of life for women with gynaecological cancer by conducting research.
We conduct and promote clinical trials and undertake multidisciplinary research into the causes, prevention and treatments of gynaecological cancers.
Research Community Volunteers will have the opportunity to contribute to ANZGOG research at every stage of the development process.
Community volunteers will lend their voices to research discussions sharing their personal perspective and representing the broader views of people with lived experience of gynaecological cancer.
Opportunities range from sharing your lived experience as a participant on a research grant working party or a Trial Management Committee, through to Research Advisor and Expert roles requiring additional levels of education and expertise in research analysis.
Gynaecological cancer research is critically needed but critically underfunded. WomenCan is the fundraising arm of ANZGOG, supporting ANZGOG by funding our programs to improve life for women with gynaecological cancer.
WomenCan’s mission is to engage the community to fund pioneering discoveries that will enable women with a gynaecological cancer to live better and live longer.
WomenCan believes the power of the collective, united in a common purpose, can make a real difference in the lives of women with gynaecological cancers.
ANZGOG’s Survivors Teaching Students (STS) Program is a ground-breaking volunteer program that brings gynaecological cancer survivors and caregivers into the classrooms of health professional students to teach them about women’s experiences with the diseases.
Survivors and caregivers are in a unique position to help students understand the ‘lived experience’ of a gynaecological cancer, including the psychosocial impact, and the importance of timely diagnosis, good health communication and compassionate care.
By joining STS and sharing your story, you will have the opportunity to impact the future care of women diagnosed with a gynaecological cancer, with participating students reporting not only increased understanding of gynaecological cancers but also a deeper understanding of the patient experience to take forward into their practice.
Since the program began at ANZGOG in 2017, our volunteers have shared their stories with more than 11,000 students across Australia and New Zealand.
